HELP Helus Pharma
Helus Pharma (HELP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: September 21, 2026 , by Halstead Michael .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Halstead Michael | Chief Executive Officer | Buy | 100,000 | $13.47 | $1.3M | 168,568 | |
| Glavine Paul 2 fills | Chief Growth Officer | Buy | 200,000 | $12.47 | $2.5M | 4,271,252 | |
| So Eric H. L. | Executive Chair | Buy | 100,000 | $12.39 | $1.2M | 4,465,014 | |
| So Eric H. L. | Executive Chair | Buy | 100,000 | $12.09 | $1.2M | 4,365,014 | |
| Glavine Paul | Chief Growth Officer | Buy | 100,000 | $11.78 | $1.2M | 4,171,252 | |
| So Eric H. L. | Executive Chair | Buy | 95,000 | $11.80 | $1.1M | 4,265,014 | |
| Glavine Paul | Chief Growth Officer | Buy | 90,000 | $11.59 | $1.0M | 4,071,252 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.